Patient-Initiated Follow-Up in Ovarian Cancer
- PMID: 37185389
- PMCID: PMC10136438
- DOI: 10.3390/curroncol30040276
Patient-Initiated Follow-Up in Ovarian Cancer
Abstract
This study aimed to assess the feasibility of patient-initiated follow-up (PIFU) in combination with regular tumour marker monitoring as an alternative to conventional hospital follow-up for ovarian cancer survivors. Women who had recently completed treatment for ovarian cancer and had a raised pre-treatment tumour marker were recruited. Participants were allocated to PIFU (intervention group) or conventional hospital follow-up (control group) according to their own preference. Both groups had regular tumour marker monitoring. The change in fear of cancer recurrence (FCR) score as measured by the FCR inventory, and the supportive care need (SCN) scores as measured by the SCN survey at baseline and at 6 months between PIFU and hospital follow-up were compared. Out of 64 participants, 37 (58%) opted for hospital follow-up and 27 (42%) opted for PIFU. During the 6-month study period, there was no significant difference in the change of FCR between the two groups (p = 0.35). There was a significant decrease in the sexuality unmet needs score in the intervention group from baseline to 6-month FU (mean difference -8.7, 95% confidence interval -16.1 to -1.4, p = 0.02). PIFU with tumour marker monitoring is a feasible follow-up approach in ovarian cancer survivorship care. FCR and SCN were comparable between PIFU and conventional hospital follow-up.
Keywords: cancer survivorship; fear of cancer recurrence; ovarian cancer; patient-initiated follow-up; supportive care needs.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- The Global Cancer Observatory Cancer Today. [(accessed on 11 November 2022)]. Available online: https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-s....
-
- National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Cervical Cancer. [(accessed on 11 November 2022)]. Available online: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1426.
-
- Salani R., Backes F.J., Fung M.F.K., Holschneider C.H., Parker L.P., Bristow R.E., Goff B.A. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am. J. Obstet. Gynecol. 2011;204:466–478. doi: 10.1016/j.ajog.2011.03.008. - DOI - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
